Trigeminal neuralgia

Global Trigeminal Neuralgia (Tic Douloureux) Clinical Trials Research Review 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 14, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Database, Decision-making, Trigeminal neuralgia, Trial, Clinical trial, Dietary supplement, Pharmaceutical industry

The "Trigeminal Neuralgia (Tic Douloureux) - Global Clinical Trials Review, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Trigeminal Neuralgia (Tic Douloureux) - Global Clinical Trials Review, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This clinical trial report provides an overview of Trigeminal Neuralgia (Tic Douloureux) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Trigeminal Neuralgia (Tic Douloureux).
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Williams Hart’s $12.45M Truck Accident Award OK’d By Texas Court

Retrieved on: 
Monday, April 4, 2022
Trucking, Legal, Professional Services, Transport, District court, Life, Family, LLP, Injury, New Prime Inc. v. Oliveira, Trigeminal neuralgia, Female, Lawyer, Insurance

A Texas appellate court approved the $12.45M jury settlement last week in favor of a couple injured in a rear-end truck accident in 2012.

Key Points: 
  • A Texas appellate court approved the $12.45M jury settlement last week in favor of a couple injured in a rear-end truck accident in 2012.
  • The victims' attorneys, Jim Hart and Margot Trevino of Williams Hart Boundas Easterby, LLP, won the substantial verdict in 2019 in the 129th District Court of Harris County, Texas.
  • So the sooner you reach out to an experienced truck accident attorney, the more likely you will receive fair compensation.
  • Our team of truck accident lawyers is dedicated to holding truck drivers accountable and getting victims the maximum compensation.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announces continuous sales growth in ZTlido® with preliminary gross sales of approximately $8.1 million during the month of March 2022 and $18.4 million for 1Q2022

Retrieved on: 
Monday, April 4, 2022
Private Securities Litigation Reform Act, Therapy, Risk, Lidocaine, Vaccine, SEC, RTX, Securities Act of 1933, Time, Nasdaq, Regulation of tobacco by the U.S. Food and Drug Administration, GLOBE, Proxy, Postherpetic neuralgia, Population, Sale, Fibromyalgia, Sciatica, Pain, Autoimmune disease, Quality of life, Chronic pain, Facility, Neuropathic pain, Dexamethasone, Low back pain, Phase, Combined, PALO, Form, Osteoarthritis, Forward-looking statement, Growth, SP-102, Failure, Name, Prospectus, Combination company, NCT, TRPV1, Trigeminal neuralgia, Awareness, FDA, Patient, BCA, Antibody, Adoption, Company, Cancer, PHN, Food, SP-104, Capsule, COVID-19, Physician, Radiculopathy, Acquisition, Online gambling, Pharmaceutical industry, Security (finance)

ZTlido sold $8.1 million in March 2022 compared to $5.3 million in March 2021.

Key Points: 
  • ZTlido sold $8.1 million in March 2022 compared to $5.3 million in March 2021.
  • In 1Q2022, the preliminary unaudited gross sales for ZTlido are approximately $18.4 million, compared to $14.6 million in 1Q2021, representing a growth of 26%.
  • We are pleased with the progress we have made to ensure patient and physician awareness, access, and adoption to ZTlido.
  • The boards of directors of each of VCKA, Scilex and Sorrento have unanimously approved the proposed transaction.

Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients With Severe Pneumonia Due to COVID-19

Retrieved on: 
Thursday, March 31, 2022
Ventilation, Inflammation, Private Securities Litigation Reform Act, PDX, Therapy, Risk, Osteoarthritis, Trial of the century, Forward-looking statement, Clinical trial, HIV disease progression rates, TKI, Survival, Vaccine, Osimertinib, Sciatica, Cancer, CEO, PHN, EGFR, Cyprus Securities and Exchange Commission, NSCLC, Neoplasm, Pain, Autoimmune disease, RTX, Security (finance), Safety, Intention, TRPV1, Prostate cancer, Mutation, BTK, Phosphorylation, GLOBE, Trigeminal neuralgia, SAN, Annual report, FDA, Acute respiratory distress syndrome, Patient, Pneumonia, Large-cell lung carcinoma, Antibody, Pharmaceutical industry, Generic drug, COVID-19

Sorrento will be starting a multicenter, multinational Phase 3 study with a Phase 2 run-in to identify the recommended Phase 3 dose (RP3D) and to demonstrate the safety and efficacy of Abivertinib in patients with respiratory compromise due to COVID-19.

Key Points: 
  • Sorrento will be starting a multicenter, multinational Phase 3 study with a Phase 2 run-in to identify the recommended Phase 3 dose (RP3D) and to demonstrate the safety and efficacy of Abivertinib in patients with respiratory compromise due to COVID-19.
  • SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc.(Nasdaq: SRNE, "Sorrento"), announced today that the FDA has given clearance for Sorrento to commence the Phase 3 clinical trial of Abivertinib in severe COVID-19 patients (hospitalized patients with respiratory compromise requiring oxygen supplementation).
  • The clinical trial will be conducted in 2 phases, and the initial run-in will define the RP3D.
  • RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients.

Noema Pharma to Attend and Present at Stifel 2022 CNS Days

Retrieved on: 
Friday, March 25, 2022
Trigeminal neuralgia, Company, Tourette syndrome, Seizure, Lists of diseases, Sofinnova, CNS, Tuberous sclerosis complex tumor suppressors, Glutamate (neurotransmitter), PDE10A, TSC, GLOBE, Polaris Partners, Patient, Pharmaceutical industry, Noema

BASEL, Switzerland, March 25, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical-stage company targeting orphan and large-market central nervous system (CNS) diseases, today announces it will participate in the Stifel 2022 CNS Days conference, being held virtually from March 28 to 29, 2022.

Key Points: 
  • BASEL, Switzerland, March 25, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical-stage company targeting orphan and large-market central nervous system (CNS) diseases, today announces it will participate in the Stifel 2022 CNS Days conference, being held virtually from March 28 to 29, 2022.
  • Management will also present the latest development of Noema to investors and will host 1:1 investor meetings.
  • Noema Pharma ( www.noemapharma.com ) is a Swiss-based company targeting neurological disorders characterized by imbalanced neuronal networks.
  • Noema Pharma was founded with the leading venture capital firm Sofinnova Partners.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connection with the Closing of the Merger with Vickers Vantage

Retrieved on: 
Friday, March 25, 2022
Private Securities Litigation Reform Act, Therapy, Risk, Vaccine, SEC, CEO, RTX, Securities Act of 1933, Time, Nasdaq, Regulation of tobacco by the U.S. Food and Drug Administration, GLOBE, Security (finance), Proxy, Postherpetic neuralgia, Population, Sale, Fibromyalgia, Sciatica, Pain, Autoimmune disease, Quality of life, LLC, Chronic pain, Facility, U.S. Securities and Exchange Commission, Dexamethasone, Low back pain, Phase, Combined, PALO, Form, Osteoarthritis, Forward-looking statement, SP-102, Failure, Name, Prospectus, Combination company, NCT, TRPV1, B. Riley Financial, Trigeminal neuralgia, FDA, Patient, BCA, Antibody, Company, Cancer, PHN, Food, SP-104, Capsule, COVID-19, Physician, Fast track (FDA), Radiculopathy, Acquisition, Management, Pharmaceutical industry

The Facility would become effective in connection with the closing of the previously announced pending merger with Vickers Vantage Corp I (Vickers).

Key Points: 
  • The Facility would become effective in connection with the closing of the previously announced pending merger with Vickers Vantage Corp I (Vickers).
  • Scilex would not be obligated to utilize any of the $5 billion facility and would be able to enter other financing transactions.
  • The term sheet contemplates that in connection with the closing of the merger with Vickers, Scilex would enter into definitive agreements with respect to the Facility.
  • The boards of directors of each of VCKA, Scilex and Sorrento have unanimously approved the proposed transaction.

American Shared Hospital Services Reports Fourth Quarter and Year End 2021 Financial Results

Retrieved on: 
Thursday, March 24, 2022
EBITDA, Total, PST, Company, Risk, Life, Century, AMS, Home After Three Months Away, Trigeminal neuralgia, Webcast, Growth, Loss, NYSE, GAAP, IGRT, Malignancy, CMS, HVS Global Hospitality Services, EST, The Twelve Months, IMRT, U.S. Securities and Exchange Commission, PBRT, Radiosurgery, Pectus carinatum, Depreciation, Acquisition, Annual general meeting, CA, Proton therapy, Orlando Health, COVID-19, GLOBE, Income, Medicare, Center for Medicare and Medicaid Innovation, Center, SAN, Annual report, Leeds Gamma Knife Centre, Income tax, Security (finance), Pharmaceutical industry, Bookkeeping, Video game, Cryptocurrency, Cutlery, Insurance, Lithium, Bank, Proton, Medicaid

SAN FRANCISCO, CA, March 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the fourth quarter and full year ending December 31, 2021.

Key Points: 
  • SAN FRANCISCO, CA, March 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the fourth quarter and full year ending December 31, 2021.
  • Operating income for the fourth quarter of 2021 was $723,000 compared to an operating loss of $8,543,000 in the fourth quarter of 2020, including the write-down of impaired assets of $105,000 and $8,264,000 in the fourth quarter of 2021 and 2020, respectively.
  • Revenue for the Company's Gamma Knife operations decreased 6.3% to $3,004,000 for the fourth quarter of 2021 compared to $3,205,000 for the fourth quarter of 2020.
  • Adjusted EBITDA, a non-GAAP financial measure, was $2,150,000 for the fourth quarter of 2021, compared to $2,538,000 for the fourth quarter of 2020.

Revitalist Increases Clinic Count to 10 with the Acquisition of a Virginia Ketamine Clinic

Retrieved on: 
Tuesday, March 29, 2022
Health, Mental Health, Other Health, Wellness, Company, Acquisition, FSE, USD, Trigeminal neuralgia, CALM, United States Navy, Clinic, Emergency medicine, Fibromyalgia, PTSD, Ketamine, CEO, Suite, Agreement, Lists of diseases, RSD, Health, Chronic pain, Tripura Merger Agreement, CRPS, Anxiety, OCD, Depression, OTC, Patient, CSE, Pharmaceutical industry, Alchemy

REVITALIST LIFESTYLE AND WELLNESS LTD. (Revitalist or the Company) (CSE: CALM) (CSNX: CALM.CN) (OTC: RVLWF) is pleased to announce that has it has entered into a definitive agreement (Merger Agreement) to acquire Alchemy Wellness (Alchemy) a ketamine clinic (Acquisition) located in Richmond, Virginia (Virginia Clinic).

Key Points: 
  • REVITALIST LIFESTYLE AND WELLNESS LTD. (Revitalist or the Company) (CSE: CALM) (CSNX: CALM.CN) (OTC: RVLWF) is pleased to announce that has it has entered into a definitive agreement (Merger Agreement) to acquire Alchemy Wellness (Alchemy) a ketamine clinic (Acquisition) located in Richmond, Virginia (Virginia Clinic).
  • The Virginia Clinic is located at 8639 Mayland Drive, Suite 102, Richmond, Virginia.
  • With over 62,000 square feet of facility space, we are the largest publicly listed ketamine focused treatment chain in the United States based on clinic size.
  • The Clinic provides ketamine infusion treatments for many mood disorders, including depression, post-partum depression, bipolar depression, PTSD, OCD, and anxiety.

10-Year Data Shows Accuray CyberKnife® System Provides Long-Lasting Relief of the Excruciating Pain Caused by Trigeminal Neuralgia

Retrieved on: 
Thursday, March 31, 2022
Trigeminal neuralgia, Private Securities Litigation Reform Act, Risk, Face, Radiosurgery, Skull, LinkedIn, Radiation, NASDAQ, Forward-looking statement, Synchrony, Cyberknife, SEC, Head, Lists of diseases, Woman, Motion, Neoplasm, Neurosurgery, Trigeminal nerve, Man, U.S. Securities and Exchange Commission, Pain, CDI, Injection, Security (finance), Artificial intelligence, Chronic pain, Safety, Twitter, Time, Brain, Movement, YouTube, Patient, Alma, Algorithm, Medical device, Dentistry, Medical imaging, Facebook

SUNNYVALE, Calif., March 31, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that long-term follow-up data from a study of men and women with trigeminal neuralgia (TN) showed 72 percent continued to experience pain relief 10 years after receiving image-guided robotic radiosurgery treatments delivered with the CyberKnife® System. The study abstract, titled "Robotic Image-Guided Radiosurgery for Trigeminal Neuralgia: Results after 10 Years," was recognized as Best Clinical Abstract at the recent 2022 Radiosurgical Society Meeting in Carlsbad, California.

Key Points: 
  • Pain can be brought on from the lightest of touches to the face, even a gently breeze can start a painful attack.
  • "Many people don't understand how debilitating the chronic pain associated with trigeminal neuralgia can be.
  • They demonstrate that with treatment options like CyberKnife radiosurgery, we can provide our patients long-term pain control without a rigid head frame, surgery or medications.
  • The Cyberknife Center of CDI (Milan) treated 668 patients with TN during the last 12 years;10-year data is available for 84 patients.

Sorrento Reports Promising Results With a Universal Chimeric mRNA COVID-19 Vaccine That Elicits Potent Neutralizing Antibodies and Protection Against Omicron (BA.1 and BA.2) and Delta Variants

Retrieved on: 
Sunday, March 20, 2022
Serum, Private Securities Litigation Reform Act, Therapy, Risk, Vaccination, ACE2, Osteoarthritis, Trial of the century, WA1, Forward-looking statement, NAB, Furin, Vaccine, EUA, Volatile organic compound, Time-invariant system, Sciatica, Cancer, CEO, Severe acute respiratory syndrome coronavirus 2, PHN, U.S. Securities and Exchange Commission, Preprint, Pain, RTX, Autoimmune disease, Security (finance), Intention, RNA transfection, TRPV1, Mutation, Lists of countries and territories, GLOBE, Lance, Animal, Trigeminal neuralgia, RBD, SAN, Annual report, FDA, Patient, Infection, Antibody, Pharmaceutical industry, Generic drug, S1, Delta, Omicron, COVID-19

Sorrentos designer mRNA vaccine, utilizing a chimeric mRNA that incorporates the Delta receptor binding domain (RBD) into the Omicron spike protein, provided strong, broad-spectrum protection against both BA.1 and BA.2 sublineages of Omicron, and Delta variant in immunized animals.

Key Points: 
  • Sorrentos designer mRNA vaccine, utilizing a chimeric mRNA that incorporates the Delta receptor binding domain (RBD) into the Omicron spike protein, provided strong, broad-spectrum protection against both BA.1 and BA.2 sublineages of Omicron, and Delta variant in immunized animals.
  • Sorrento intends to develop and seek EUA approval of this next-generation mRNA vaccine in Mexico and other developing countries.
  • These changes result in enhanced transmissibility and breakthrough cases in the presence of antibodies induced by vaccination with the wild-type SARS-CoV-2 spike mRNA vaccines.
  • This novel designer chimeric mRNA vaccine may offer a powerful strategy to develop mRNA vaccines with universal protection against SARS-CoV-2 and its major VOCs.